Nykode Therapeutics AS (VACBF)
- Previous Close
0.0000 - Open
0.3150 - Bid 0.1510 x 306100
- Ask 0.2310 x 313300
- Day's Range
0.3150 - 0.3150 - 52 Week Range
0.2170 - 1.5000 - Volume
2,500 - Avg. Volume
15 - Market Cap (intraday)
89.767M - Beta (5Y Monthly) 1.42
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1200 - Earnings Date May 14, 2025
- Forward Dividend & Yield 0.10 (34.77%)
- Ex-Dividend Date May 27, 2025
- 1y Target Est
--
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
nykode.comRecent News: VACBF
View More
Performance Overview: VACBF
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VACBF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VACBF
View MoreValuation Measures
Market Cap
76.95M
Enterprise Value
-35.01M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.25
Price/Book (mrq)
0.66
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.70%
Return on Equity (ttm)
-25.25%
Revenue (ttm)
9.16M
Net Income Avi to Common (ttm)
-38.82M
Diluted EPS (ttm)
-0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
115.4M
Total Debt/Equity (mrq)
2.52%
Levered Free Cash Flow (ttm)
-34.3M